Format

Send to

Choose Destination
Expert Rev Vaccines. 2012 Jun;11(6):721-31. doi: 10.1586/erv.12.39.

Cancer vaccines: should we be targeting patients with less aggressive disease?

Author information

1
Department of Surgery, General Surgery Service, Brooke Army Medical Center, San Antonio, TX, USA.

Abstract

There is enthusiasm for using vaccines to stimulate the immune system to treat cancer. In this article, the authors review the evolution of vaccines evaluated in clinical trials, starting with Phase III trials in metastatic disease and progressing to trials in the adjuvant setting. Data from these trials suggest that cancer vaccines may be more effective in patients with lower volume disease, and data from the E75 peptide vaccine trials suggest that vaccines may be most effective in less aggressive disease.

PMID:
22873128
DOI:
10.1586/erv.12.39
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center